Canada's TerrAscend Q4 revenue beats estimates
Overview
Canada cannabis firm's Q4 revenue beat analyst expectations
Company renewed share buyback program for up to $10 mln USD during the year
Outlook
TerrAscend says it expects sustainable growth and shareholder value in 2026 and beyond
TerrAscend plans to focus M&A strategy on accretive transactions aligned with strategic goals
Result Drivers
WHOLESALE AND PRODUCT PERFORMANCE - Co cited sequential increases in both retail and wholesale revenue, with branded products ranking highly in Maryland and Pennsylvania
Company press release: ID:nGNX62XBPy
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $66.10 mln | $64.68 mln (4 Analysts) |
Q4 Gross Margin |
| 52.1% |
|
Q4 Net Income from Cont. Ops |
| -$500,000 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Terrascend Corp is C$2.00, about 119.8% above its March 11 closing price of C$0.91
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
